Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP. Barton P, et al. Among authors: utterback bg. Pediatrics. 2004 Jan;113(1 Pt 1):7-17. doi: 10.1542/peds.113.1.7. Pediatrics. 2004. PMID: 14702440 Clinical Trial.
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D. Dhainaut JF, et al. Among authors: utterback bg. Crit Care Med. 2003 Sep;31(9):2291-301. doi: 10.1097/01.CCM.0000085089.88077.AF. Crit Care Med. 2003. PMID: 14501959 Clinical Trial.
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Abraham E, et al. Among authors: utterback bg. N Engl J Med. 2005 Sep 29;353(13):1332-41. doi: 10.1056/NEJMoa050935. N Engl J Med. 2005. PMID: 16192478 Free article. Clinical Trial.
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Dhainaut JF, et al. Among authors: utterback bg. Intensive Care Med. 2003 Jun;29(6):894-903. doi: 10.1007/s00134-003-1731-1. Epub 2003 Apr 24. Intensive Care Med. 2003. PMID: 12712239 Clinical Trial.
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569].
Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF; PROWESS Sepsis Study Group. Kinasewitz GT, et al. Among authors: utterback b. Crit Care. 2004 Apr;8(2):R82-90. doi: 10.1186/cc2459. Epub 2004 Feb 10. Crit Care. 2004. PMID: 15025782 Free PMC article. Clinical Trial.
Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.
LaRosa SP, Opal SM, Utterback B, Yan SC, Helterbrand J, Simpson AJ, Chaowagul W, White NJ, Fisher CJ Jr. LaRosa SP, et al. Among authors: utterback b. Int J Infect Dis. 2006 Jan;10(1):25-31. doi: 10.1016/j.ijid.2005.06.001. Epub 2005 Nov 11. Int J Infect Dis. 2006. PMID: 16290015 Free article. Clinical Trial.
34 results